- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04393155
COVID Cohort Study
Understanding Immunology and Patient Outcomes of COVID-19: A 1-Year Longitudinal Follow-up Study of Hospitalized Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The novel coronavirus (SARS-CoV-2) and associated COVID-19 illness has quickly spread worldwide, with substantial morbidity and mortality. Early data suggest that most patients with severe COVID-19 (i.e., experiencing acute respiratory failure (ARF) in an intensive care unit) may have cytokine release syndrome and other major effects on the innate and adaptive immune systems. However, there is limited understanding of both the inflammatory/immunological and the clinical course of COVID-19, with no robust data published beyond hospital discharge. Based on prior literature from acute viral illnesses, such as Ebola and Severe Acute Respiratory Syndrome (SARS), persistent functional impairments in COVID-19 survivors is expected. Despite the importance of these issues, very few studies have ever investigated the biological mechanisms underlying persistent functional impairments after ARF. Hence, understanding the short- and longer-term biological and clinical outcomes of patients with COVID-19, and investigating associations between inflammation and clinical outcomes is important to design acute therapies and recovery-focused interventions.
To address critical gaps in knowledge, the investigators propose a 2-center longitudinal cohort study of hospitalized COVID-19 patients via an Administrative Supplement to our existing grant (R01HL132887, MPIs Stapleton and Needham). Investigators will study COVID-19 patients with ARF who have either severe disease (requiring mechanical ventilation, non-invasive ventilation, or high flow nasal cannula oxygen support) or non-severe disease (new or increased supplemental oxygen requirement, without meeting severe criteria). Researchers will perform an in-depth evaluation of inflammatory/immunological, physical, pulmonary, and neuropsychological status during hospitalization, and over 3, 6, and 12-month follow-up. Feasibility for accomplishing this prospective study is demonstrated by 1) a successful existing collaboration between the University of Vermont (UVM) and Johns Hopkins University (JHU), supported by multiple NIH grants, and 2) the current and projected COVID-19 census at both hospital systems. The investigators have the existing infrastructure, expertise, and personnel to enroll 225 patients with COVID-19, and longitudinally follow survivors for 12 months, to investigate short-term and longer-term inflammatory/immunologic and clinical outcomes during this pandemic.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Vermont
-
Burlington, Vermont, United States, 05405
- University of Vermont College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult (≥18 years old) at the time of consent
- Positive COVID-19 test result or highly suspicious for COVID-19 infection and have a test pending
- Acute Respiratory Failure (new requirement for supplemental oxygen or acute increase in required supplemental oxygen)
Exclusion Criteria:
- Expected death or withdrawal of life-sustaining treatments within 3 days
- Unable to walk ≥150 feet prior to COVID-19 (due to 6-minute walk test being primary outcome for in-person testing)
- Hemoglobin ≤7.0 at the time of consent
- Pre-existing cognitive/language impairment prohibiting clinical outcomes assessment
- Prior lung resection (due to spirometry as part of in-person outcome assessment)
- Unable to provide consent and no legally authorized representative (LAR) identified or reached by phone
- Pregnant
- Incarcerated
- Homelessness
- Physician declines patient enrollment (attending physician or study physician)
- Patient or LAR do not consent to participate in the study
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
COVID-19+
Hospitalized patients with acute respiratory failure (new oxygen requirement) due to COVID-19
|
This is observational -- there is no intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Six minute walk distance (6MWD)
Time Frame: 3 months after hospital admission
|
Exercise capacity
|
3 months after hospital admission
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Six minute walk distance (6MWD)
Time Frame: 6 months, 12 months after hospital admission
|
Exercise capacity
|
6 months, 12 months after hospital admission
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: 3 months, 6 months, 12 months after hospital admission
|
Symptoms of anxiety and depression.
Both anxiety and depression subscales are scored from 0-21, with higher scores indicating more symptoms.
|
3 months, 6 months, 12 months after hospital admission
|
EuroQol Group standardized measure of health status (EQ-5D-5L)
Time Frame: 3 months, 6 months, 12 months after hospital admission
|
Health-related quality of life.
The EQ-5D-5L is scored from 0-100, with a higher score indicating better health status.
|
3 months, 6 months, 12 months after hospital admission
|
MoCA-BLIND
Time Frame: 3 months, 6 months, 12 months after hospital admission
|
Mental and Cognitive Functioning.
The MoCA-BLIND is scored from 1-22, with higher scores indicating better cognitive function.
|
3 months, 6 months, 12 months after hospital admission
|
Health Care Utilization Survey (HUS)
Time Frame: 3 months, 6 months, 12 months after hospital admission
|
Health Care Utilization
|
3 months, 6 months, 12 months after hospital admission
|
Death
Time Frame: 3 months, 6 months, 12 months after hospital admission
|
Mortality
|
3 months, 6 months, 12 months after hospital admission
|
Forced vital capacity (FVC)
Time Frame: 3 months, 6 months, 12 months after hospital admission
|
The maximum volume of gas expired when the patient exhales as forcefully and rapidly as possible after a maximal inspiration.
Obtained by spirometry.
|
3 months, 6 months, 12 months after hospital admission
|
Forced expiratory volume in 1 second (FEV1)
Time Frame: 3 months, 6 months, 12 months after hospital admission
|
Measure of the volume expired over the first second of an FVC maneuver.
Obtained by spirometry
|
3 months, 6 months, 12 months after hospital admission
|
4-meter timed walk
Time Frame: 3 months, 6 months, 12 months after hospital admission
|
Gait speed
|
3 months, 6 months, 12 months after hospital admission
|
Peripheral blood mononuclear cell type: CD4+ T cells (#cells/ml)
Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Measured by cell staining and flow cytometry.
PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.
|
study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Peripheral blood mononuclear cell type: CD8+ T cells (#cells/ml)
Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Measured by cell staining and flow cytometry.
PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.
|
study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Peripheral blood mononuclear cell type: B cells (#cells/ml)
Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Measured by cell staining and flow cytometry.
PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.
|
study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Peripheral blood mononuclear cell type: NK cells (#cells/ml)
Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Measured by cell staining and flow cytometry.
PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.
|
study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Peripheral blood mononuclear cell type: monocytes (#cells/ml)
Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Measured by cell staining and flow cytometry.
PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.
|
study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Circulating markers of inflammation: C-Reactive Protein (CRP) (mg/l)
Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
|
study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Circulating markers of inflammation: Interleukin 6 (IL-6) (pg/ml)
Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
|
study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Circulating markers of inflammation: Interleukin 8 (IL-8) (pg/ml)
Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
|
study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Circulating markers of inflammation: Interferon gamma (IFNg) (pg/ml)
Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
|
study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Circulating markers of inflammation: Interferon alpha (IFNa) (pg/ml)
Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
|
study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Circulating markers of inflammation: Tumor necrosis factor alpha (TNFa) (pg/ml)
Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
|
study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Circulating markers of inflammation: Interleukin 1 beta (IL-1b) (pg/ml)
Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
|
study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-540
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on COVID-19+ observational
-
University of VermontActive, not recruitingCovid19United States
-
AstraZenecaCompleted
-
Hasanuddin UniversityChulalongkorn UniversityCompleted
-
Raphael SerreauAssistance Publique - Hôpitaux de Paris; University Hospital, Paris; François...CompletedCoronavirus InfectionFrance
-
Melike CengizCompleted
-
AstraZenecaCompleted
-
University of PennsylvaniaPublic Health Management CorporationCompleted
-
University of Texas at AustinUnknownFood InsecurityUnited States
-
University of PennsylvaniaPublic Health Management CorporationCompleted
-
Duke UniversityNorth Carolina Department of Health and Human ServicesCompleted